AbbVie Extends Reach Of Regenxbio’s Wet AMD Program

Deal May Indicate Renewed Pharma Appetite For Gene Therapy

The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
Regenxbio stands to benefit from AbbVie's presence in eye care • Source: Shutterstock

Regenxbio Inc. will have sufficient resources to extend the global reach of RGX-314, its gene therapy for wet age-related macular degeneration (AMD) and diabetic retinopathy (DR), through a partnership with AbbVie Inc. worth potentially as much as $1.75bn. The company also stands to benefit from AbbVie’s expertise in eye diseases, without which the gene therapy maker may have found itself left to compete alone against other large drug makers in the space.

Rockville, MD-based Regenxbio and Chicago-based AbbVie said on 13 September that they entered into a development and commercialization deal, whereby...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.